{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-113960","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2024-10-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.686701+00:00","generated_at":"2026-05-30T16:16:47.618514+00:00","sec_items":["1.02","2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alaunos terminates key license with Precigen, pivots to oral obesity program; cash runway into Q1 2025","bullets":["Terminated Amended and Restated License Agreement with Precigen effective Oct 4, 2024; Sleeping Beauty patent expiry in 2026 cited.","Continues prosecuting TCR IP targeting KRAS, TP53, EGFR mutations and hunTR discovery platform.","Exploring strategic alternatives including acquisition, merger, reverse merger, or sale of assets.","Progressing internally developed small molecule oral obesity program; CMDO engaged for API manufacturing.","Cash runway extended into Q1 2025 via overhead reductions; in vitro testing planned Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-113960","json":"https://secwatch.observer/filing/0000950170-24-113960.json","markdown":"https://secwatch.observer/filing/0000950170-24-113960.md","text":"https://secwatch.observer/filing/0000950170-24-113960.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000095017024113960/0000950170-24-113960-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000095017024113960/tcrt-20241004.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T16:16:47.618514+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}